Thursday, September 03, 2020 1:16:35 AM
Pfizer partnership? I'm skeptical.
_________________________
A interesting find on the yahoo board. Pfizer possible partner under a new program they announced in June??? Both have scheduled public reports on Sept. 15th. Only 2 bio companies having public announcements that day.
s the Pfizer Breakthrough Growth Initiative?
The Pfizer Breakthrough Growth Initiative will focus on making non-controlling equity investments in clinical-stage public companies, with a primary focus on companies with small- to medium-sized market capitalizations across a range of therapeutic categories that are consistent with Pfizer’s core areas of focus: Internal Medicine, Inflammation & Immunology, Oncology, Rare Disease, Vaccines and Hospital. Partner companies may also have the opportunity to access Pfizer’s significant expertise and resources in research, clinical development and manufacturing.
Is the Pfizer Breakthrough Growth initiative related to COVID-19 pandemic?
In addition to our core therapeutic areas of focus, companies developing treatments or vaccines for COVID-19 will be considered as potential partners.
While the launch of this new initiative is not specifically tied to the pandemic, the resulting uncertainty in the future financial markets may increase the need for many companies in the biotech community to seek alternative funding sources in order to help execute their long-term strategic plans.
Is the Pfizer Breakthrough Growth Initiative limited to U.S. biotechnology companies?
No. As with all of our partnering activities, we seek to collaborate with companies that are working on breakthrough science, no matter where the company is located."
https://www.pfizer.com/news/hot-topics/announcing_the_pfizer_breakthrough_growth_initiative_a_new_program_to_support_continued_biotechnology_innovation
_________________________
A interesting find on the yahoo board. Pfizer possible partner under a new program they announced in June??? Both have scheduled public reports on Sept. 15th. Only 2 bio companies having public announcements that day.
s the Pfizer Breakthrough Growth Initiative?
The Pfizer Breakthrough Growth Initiative will focus on making non-controlling equity investments in clinical-stage public companies, with a primary focus on companies with small- to medium-sized market capitalizations across a range of therapeutic categories that are consistent with Pfizer’s core areas of focus: Internal Medicine, Inflammation & Immunology, Oncology, Rare Disease, Vaccines and Hospital. Partner companies may also have the opportunity to access Pfizer’s significant expertise and resources in research, clinical development and manufacturing.
Is the Pfizer Breakthrough Growth initiative related to COVID-19 pandemic?
In addition to our core therapeutic areas of focus, companies developing treatments or vaccines for COVID-19 will be considered as potential partners.
While the launch of this new initiative is not specifically tied to the pandemic, the resulting uncertainty in the future financial markets may increase the need for many companies in the biotech community to seek alternative funding sources in order to help execute their long-term strategic plans.
Is the Pfizer Breakthrough Growth Initiative limited to U.S. biotechnology companies?
No. As with all of our partnering activities, we seek to collaborate with companies that are working on breakthrough science, no matter where the company is located."
https://www.pfizer.com/news/hot-topics/announcing_the_pfizer_breakthrough_growth_initiative_a_new_program_to_support_continued_biotechnology_innovation
Recent RLFTF News
- MindMaze Therapeutics Announces Initiation of Coverage by Baader Bank • ACCESS Newswire • 03/19/2026 06:35:00 AM
- MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics • ACCESS Newswire • 12/23/2025 06:20:00 AM
- Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics • ACCESS Newswire • 12/15/2025 06:20:00 AM
- Relief Therapeutics Shareholders Approve Business Combination with NeuroX • ACCESS Newswire • 11/14/2025 05:40:00 PM
- Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032 • ACCESS Newswire • 10/29/2025 06:20:00 AM
- Micro-Cap Biotech Skyrockets on FDA Pediatric Disease Nod • AllPennyStocks.com • 05/22/2025 04:49:00 PM
